Maxim Group Starts Inovio Pharmaceuticals (INO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 +2.65%
Rating Summary:
11 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 92
Rating Summary:
11 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 92
Join SI Premium – FREE
Earlier, Maxim Group initiated coverage on Inovio Pharmaceuticals (NYSE: INO) with a Buy. PT $1.00.
For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.
Shares of Inovio Pharmaceuticals closed at $0.64 yesterday.
For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.
Shares of Inovio Pharmaceuticals closed at $0.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt Starts Nebius Group (NBIS) at Buy
- Yorkville Ives Starts Quantinuum Inc (QNT) at Outperform
- Yorkville Ives Starts Rubrik Inc (RBRK) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
